TNFSF10 and glioblastoma: Our results show that hAMSC-SBE4-TRAIL released its therapeutic payload in response to TGF-β and they exhibit high safety criteria and selectively induce apoptosis in GBM cells while minimizing toxicity in the normal tissue (Fig. 7).